Vardenafil (Levitra) reduces erectile dysfunction (ED) and may prevent depression in men who have had nerve-sparing prostatectomy, according to a presentation on Sept. 23 at the 10th World Congress of the International Society for Sexual and Impotence Research held in Montreal, Quebec, Canada. A second presentation suggests that the drug maintains its efficacy with repeated use.
“Men who suffer from ED following prostatectomy are among the most difficult to treat because their ED is typically severe,” lead author Gerald Brock, MD, from St. Joseph’s Health Centre in London, Ontario, Canada, says in a news release.
“The finding that Levitra significantly improved erectile function in our study patients is important because more than two-thirds of these men had severe ED.” Vardenafil is a potent and highly selective PDE5 inhibitor. In this double-blind study, 440 men with persistent ED for six months or more after nerve-sparing retropubic radical prostatectomy were randomized to treatment with placebo, vardenafil 10 mg, or vardenafil 20 mg for 12 weeks. Age range was 44 to 77 years, and baseline Erectile Function (EF) domain scores were 9.1 to 9.3, indicating that ED was generally severe.
e-Med Tools
קצר קולע וממוקד
e-Med סמינרים
אי-מד תחקירים
Medscape Tools
Journal Club
מרכזי מידע ושירות
Facebook
מידע למפרסם
מאגר תרופות
מאגר אנשי המקצוע
אינדקס שימושי
חדשות משה"ב
eMed HealthClub
מחקרים קליניים
השאירו תגובה
רוצה להצטרף לדיון?תרגישו חופשי לתרום!